Garrettson Ellis, MD
Critical Care Medicine · Memphis, TNNPI 1336145317
Payments from drug & device makers
Across 577 payments — averaging $15.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$912
- Boehringer Ingelheim$743
- United Therapeutics Corporation$611
- Genentech USA, Inc.$606
- Sanofi$551
- plus $4K from 30 others
What the payments were for
- Food & beverage$9,08799%
- Education$1061%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 164 | $2,058 |
| AstraZeneca | 45 | $912 |
| Boehringer Ingelheim | 52 | $743 |
| United Therapeutics Corporation | 31 | $611 |
| Genentech USA, Inc. | 43 | $606 |
| Sanofi | 27 | $551 |
| Insmed, Inc. | 23 | $441 |
| Harmony Biosciences LLC | 17 | $407 |
| Regeneron Healthcare Solutions, Inc. | 15 | $340 |
| Grifols USA, LLC | 19 | $336 |
| Actelion Pharmaceuticals US, Inc. | 21 | $323 |
| Mylan Specialty L.p. | 24 | $320 |
| Merck | 13 | $217 |
| AbbVie(2 entities) | 12 | $173 |
| Amgen | 8 | $144 |
| Verona Pharma, Inc. | 9 | $137 |
| La Jolla Pharmaceutical Company | 7 | $108 |
| Sunovion Pharmaceuticals Inc. | 7 | $95 |
| Bayer | 6 | $94 |
| Novartis | 6 | $93 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $92 |
| Tetraphase Pharmaceuticals, Inc. | 4 | $70 |
| Pfizer | 3 | $46 |
| Caris MPI, Inc. | 2 | $42 |
| Gilead | 2 | $32 |
| Baxter Healthcare | 1 | $25 |
| Mallinckrodt Hospital Products Inc. | 1 | $25 |
| CSL Behring | 1 | $22 |
| Pulmonx Corporation | 1 | $22 |
| Inogen, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $17 |
| Mallinckrodt Enterprises LLC | 1 | $15 |
| Advanced Respiratory, Inc | 1 | $15 |
| Viatris Specialty LLC | 1 | $14 |
| Cumberland Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$9,193 in reported general payments places this provider in the 85th percentile of 141 critical care medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 443 | $351,481 |
| NucalaMepolizumab | 20 | $93,963 |
| Breo ElliptaFluticasone/Vilanterol | 127 | $66,590 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 98 | $58,384 |
| Spiriva HandihalerTiotropium Bromide | 69 | $53,233 |
| Incruse ElliptaUmeclidinium Bromide | 89 | $35,634 |
| Spiriva RespimatTiotropium Bromide | 51 | $33,918 |
| Qvar RedihalerBeclomethasone Dipropionate | 92 | $26,851 |
| SymbicortBudesonide/Formoterol Fumarate | 56 | $17,576 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 17 | $10,723 |
| Arnuity ElliptaFluticasone Furoate | 31 | $10,629 |
| EliquisApixaban | 17 | $10,626 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 408 | $10,480 |
| Tiotropium Bromide | 28 | $9,547 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 36 | $7,699 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $2,058 | $616,680808 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat | $743 | $44,64168 claims |
| AstraZenecaSymbicort | $912 | $17,57656 claims |
| PfizerEliquis | $46 | $10,62617 claims |
| MerckDulera | $217 | $5,42114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 141 critical care medicine providers in Tennessee.
Other critical care medicine in Memphis
- Anthony MattoxMemphis$33K
- Paul DeatonMemphis$24K
- Nathan WildsMemphis$19K
- Robert AguillardMemphis$11K
- Kimberly MarshMemphis$11K
- Roy FoxMemphis$9K
- Matthew MabieMemphis$7K
- Steven WoodsMemphis$6K
- William RichardsMemphis$6K
- Michael MundayMemphis$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.